| *Together with Mode Mobile & Monument Trader’s Alliance | Special heads up! | Today at 1pm EST, Jason Bond is going to reveal exactly what growth chambers are…and why they factor so critically into his $2000 Small Account Super System! Don’t miss this → Attend HERE 1pm EST. All are welcome! | | FOCUS LIST🔎 | SES - Up over 18% in pre after announcing signing of contracts totaling up to $10 million to develop AI-enhanced Li-Metal and Li-ion batteries for EVs with two automotive OEM partners | QNRX - Up over 40% in pre after announcing licensee success in Netherton Syndrome clinical studies | VIGL - Up over 12% in pre after announcing positive data from its Phase 1 clinical trial evaluating VG-3927 for the potential treatment of Alzheimer’s disease | | *together with Mode Mobile | Today’s Fastest Growing Company Might Surprise You | | 🚨 No, it's not the publicly traded tech giant you might expect… Meet $MODE, the disruptor turning phones into potential income generators. Investors are buzzing about the company's pre-IPO offering.1 | 📲 Mode saw 32,481% revenue growth from 2019 to 2022, ranking them the #1 overall software company on Deloitte’s most recent fastest-growing companies list2 by aiming to pioneer "Privatized Universal Basic Income" powered by technology — not government. Their flagship product, EarnPhone, has already helped consumers earn & save $325M+. | 🫴 Mode’s Pre-IPO offering1 is live at $0.26/share, and 20,000+ shareholders already participated in its previous sold-out offering. They’ve just been granted the stock ticker $MODE by the Nasdaq1, and you can still invest in their pre-IPO offering at just $0.26/share before it closes. | | Mode Disclaimers | 1 Mode Mobile recently received their ticker reservation with Nasdaq ($MODE), indicating an intent to IPO in the next 24 months. An intent to IPO is no guarantee that an actual IPO will occur. | 2 The rankings are based on submitted applications and public company database research, with winners selected based on their fiscal-year revenue growth percentage over a three-year period. | 3 A minimum investment of $1,950 is required to receive bonus shares. 100% bonus shares are offered on investments of $9,950+. |
|
| | HOTLIST🔥 | SES - Up over 18% in pre after announcing signing of contracts totaling up to $10 million to develop AI-enhanced Li-Metal and Li-ion batteries for EVs with two automotive OEM partners | SES AI Corporation (SES) engages in the development and production of high-performance Lithium-metal rechargeable batteries for electric vehicles, electric vehicle take-off and landing, and other applications. | In the pre-market this morning, the company announced a major milestone for the commercial application of AI for Science for battery material discovery with contracts totaling up to $10 million. | The contracts are with two existing major global OEM partners to apply AI for Science to develop new electrolyte materials for Li-Metal and Li-ion batteries for automotive applications and are expected to result in new revenue which will be partially recognized in the fourth quarter of 2024, with the balance expected to be recognized through the first half of 2025. | Shares of SES traded up over 18% in the pre-market in reaction to the news. | | The first target for bulls is the pre-market high at $1.02. Above it, targets to the upside are $1.13, $1.50, $1.70 and $2 above that. | Below $1.02, targets to the downside are $0.90, $0.88, $0.8520 and then a gap fill at $0.8314. | | QNRX - Up over 30% in pre after announcing success in Netherton Syndrome clinical studies | Quoin Pharmaceuticals Ltd. (QNRX) is a clinical stage specialty pharmaceutical company that focuses on the development and commercialization of therapeutic products for rare and orphan diseases. | In the pre-market this morning, the company announced significant achievements in 2024 and 2025, through its Netherton Syndrome treatment. | Skinvisible granted Quoin an exclusive, royalty-bearing license to its technology for use in select rare skin diseases and for the right to use its proprietary formula for Netherton Syndrome | Key Recent Developments: | FDA clearance for Netherton Syndrome "whole body" study at Northwestern University Significant clinical improvements in both open label and pediatric studies including subject's disease classification improved from "severe" to "mild" after 6 weeks dosing No adverse events or safety concerns reported to date from each of Quoin's ongoing clinical studies in Netherton Syndrome subjects International expansion of studies to UK, Ireland, and Saudi Arabia Netherton Syndrome product QRX003 with Invisicare delivery technology licensed in 60 countries
| Shares of QNRX traded up over 30% in the pre-market in reaction to the news. | | The $0.70 area acted as support in the pre-market and now becomes a potential level of resistance. | Above it, targets to the upside are $0.74, $0.80, $0.83, $0.85, $0.90, $0.95 and then the pre market high at $0.98. Beyond that, $1.08 and $1.30 come into play. | Below $0.70, targets to the downside are $0.6730, $0.65 and then a gap fill at $0.5896. | | |
Strange options secret, not typical | Forget day trading (especially in markets like these). Trade OVERNIGHT instead! | I've uncovered a shocking way to take 100% certain events (mandated by the U.S. Government)...to target huge moves OVERNIGHT! See how these types of gains can be realized before the next BIG move: |  | *Note: Trading is hard, results not guaranteed and should not be expected to be replicated typically. |
|
|
| | VIGL - Up over 12% in pre after announcing positive data from its Phase 1 clinical trial evaluating VG-3927 for the potential treatment of Alzheimer’s disease | Vigil Neuroscience Inc. (VIGL) is a clinical-stage biotechnology company that focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. | In the pre-market this morning, the company announced positive data from its completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of AD. | Highlights inlcude: | - Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease (AD) - | - Robust and dose-dependent reductions of sTREM2 were achieved demonstrating sustained functional target engagement – | - Company plans to advance VG-3927 into a Phase 2 trial in the third quarter of 2025; Selects 25mg QD oral as a dose that fully engages desired pharmacology - | Shares of VIGL traded up over 12% in the pre-market in reaction to the news. | | The $2.20 area acted as support in the pre-market and was an important level to watch. | Above it, targets to the upside are $2.40, $2.65 and then the pre-market high at $2.89. Beyond that, $3.25 and $3.50 come into play. | Below $2.20, targets to the downside are $2.09 and then a gap fill at $2.03. | | MARKET NEWS 📰 | | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. | *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
